trial
as of 2026-07-01A Study to Evaluate the Effect of KarXT on Urological Safety
NCTId NCT07221877
at a glance
Phase 4 · Recruiting
Enrollment 60 (estimated)
Sponsored by Bristol-Myers
Primary completion 2027-12-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Recruiting
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2026-01-20
Primary completion
2027-12-30
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Indications
Sponsors
Bristol-MyersLead Sponsor
Sites
13 total
Little Rock, United StatesBellflower, United StatesGarden Grove, United StatesOrange, United StatesLauderhill, United StatesWest Palm Beach, United StatesChicago, United StatesChicago, United StatesLas Vegas, United StatesMarlton, United StatesPhiladelphia, United StatesAustin, United States
Facts & assertions
4 sourced
Enrollment
60
Phase
PHASE4
Primary Completion Date
2027-12-30
Status
RECRUITING
relationships
The graph out of here
drug
lead_sponsor
company
indication
indication
indication